Nautilus Sues Wockhardt Over Cambia ANDA

Law360, New York (April 8, 2011, 7:34 PM EDT) -- Nautilus Neurosciences Inc. launched a patent infringement suit Friday in New Jersey, seeking to prevent Wockhardt Ltd. from selling a generic version of migraine drug Cambia.

The complaint, filed in the U.S. District Court for the District of New Jersey, claims Wockhardt filed an abbreviated new drug application with the U.S. Food and Drug Administration to market and sell a generic form of diclofenac potassium for oral solution, sold under the brand name Cambia.

According to Nautilus, Cambia is an anti-inflammatory prescription drug. It is available...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.